Clonal blood changes after certain lung blood clots
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This study looks at whether a specific kind of blood-cell change (“clonal hematopoiesis”) is linked to a lung blood clot (pulmonary embolism) that happened without a clear trigger. It compares people with unprovoked clots to people with provoked clots, after checking for inherited clotting risk factors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 65 years old or younger
- You cannot have active cancer
- You must have had a proximal pulmonary embolism (a clot near the lung’s main blood vessels)
- Your clot must be either unprovoked (no clear trigger) or provoked (with a clear trigger), depending on which group you’re placed in
- You must have negative thrombophilia testing (no inherited clotting condition found)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic (inherited DNA) markers in people who have had a lung blood clot (pulmonary embolism) after having a hip or knee replacement. The goal is to understand why blood clots may happen again and help improve future risk prediction and care.
This study looks at people with interstitial lung disease (a lung scarring condition) who have new or worsening symptoms that might be caused by a blood clot in the lungs (pulmonary embolism). Doctors want to find better ways to predict which patients actually have a clot, which could lead to earlier and more accurate treatment.
This trial looks at how people do after an acute pulmonary embolism (a blood clot in the lungs). It aims to understand real-world outcomes over follow-up and may help improve how care teams track patients after treatment.
This study looks at whether a new way of grouping patients with blood clots in the lungs (pulmonary embolism) can better predict their outcomes. If you join, your health will be tracked for 30 days to see how well this new system works.
This study looks at why some people with interstitial lung disease develop blood clots while in the hospital. It may help doctors find ways to prevent these clots in the future.
This study looks at how certain blood cell changes and immune system activity may relate to blood clots in specific veins or lungs. It may help researchers understand why clots happen “without a clear cause” and how to better predict risk.
Hear when a new Pulmonary Embolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.